BROSSARD, Quebec, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the voting results of its annual and special meeting of shareholders held earlier today.
Election of directors
Mr. Georges Hébert, Mr. André Larente, Dr. Reid Maclellan, Dr. Jean-François Yale and Mr. François Côté were elected as directors of the Corporation to hold office until the closing of the next annual meeting of the shareholders, subject to the By-laws of the Corporation.
Appointment of auditor
Raymond Chabot Grant Thornton was re-appointed as auditor of the Corporation for the ensuing year.
Amendment to the stock option plan
The disinterested shareholders of the Corporation approved a special resolution pursuant to which the maximum number of common shares of the Corporation that may be issued under the stock option plan be set at 6,000,000, representing an increase of 4,000,000 common shares.
The amendment to the Corporation’s stock option plan remains subject to the TSX Venture acceptance.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. Marc-André Massue, CFO and Corporate Secretary
DIAGNOS Inc
Tel: 450-678-8882 ext. 235
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
